Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly
VRTX Vertex Pharmaceuticals Incorporated daily Stock Chart
VRTX [NASD]
Vertex Pharmaceuticals Incorporated
Healthcare | Biotechnology | USA
statements
IndexS&P 500 P/E97.54 EPS (ttm)2.25 Insider Own0.10% Shs Outstand256.94M Perf Week-1.91%
Market Cap56.26B Forward P/E32.83 EPS next Y6.67 Insider Trans-69.14% Shs Float256.80M Perf Month5.74%
Income583.80M PEG3.29 EPS next Q1.18 Inst Own98.30% Short Float1.56% Perf Quarter23.33%
Sales3.62B P/S15.54 EPS this Y99.10% Inst Trans0.42% Short Ratio3.14 Perf Half Y26.01%
Book/sh20.45 P/B10.71 EPS next Y39.02% ROA31.40% Target Price232.27 Perf Year26.27%
Cash/sh15.55 P/C14.08 EPS next 5Y29.64% ROE44.00% 52W Range151.80 - 225.66 Perf YTD32.15%
Dividend- P/FCF41.26 EPS past 5Y23.90% ROI11.20% 52W High-2.96% Beta1.48
Dividend %- Quick Ratio3.30 Sales past 5Y20.30% Gross Margin86.60% 52W Low44.26% ATR3.97
Employees2500 Current Ratio3.40 Sales Q/Q21.10% Oper. Margin21.40% RSI (14)63.44 Volatility1.98% 1.88%
OptionableYes Debt/Eq0.11 EPS Q/Q-55.40% Profit Margin59.20% Rel Volume1.06 Prev Close220.55
ShortableYes LT Debt/Eq0.10 EarningsOct 30 AMC Payout0.00% Avg Volume1.27M Price218.98
Recom1.90 SMA200.34% SMA509.66% SMA20019.91% Volume1,350,164 Change-0.71%
Nov-19-19Upgrade Guggenheim Neutral → Buy $252
Nov-12-19Initiated SunTrust Buy $235
Oct-17-19Resumed BofA/Merrill Buy $220
Sep-03-19Upgrade Goldman Neutral → Buy $226 → $254
Aug-01-19Downgrade Needham Buy → Hold
May-23-19Resumed Citigroup Buy $205
May-21-19Initiated Credit Suisse Outperform $209
Apr-12-19Initiated Evercore ISI In-line
Mar-26-19Upgrade William Blair Mkt Perform → Outperform
Mar-19-19Downgrade SVB Leerink Outperform → Mkt Perform
Feb-06-19Downgrade Maxim Group Buy → Hold
Jan-02-19Downgrade Raymond James Outperform → Mkt Perform
Oct-26-18Upgrade H.C. Wainwright Neutral → Buy $220
Oct-01-18Initiated Cantor Fitzgerald Overweight $217
Aug-07-18Reiterated Stifel Buy $182 → $200
Mar-05-18Reiterated Maxim Group Buy $195 → $200
Feb-13-18Reiterated JMP Securities Mkt Outperform $200 → $211
Feb-01-18Reiterated Barclays Overweight $180 → $200
Jan-05-18Upgrade BofA/Merrill Neutral → Buy
Oct-18-17Reiterated RBC Capital Mkts Outperform $175 → $181
Dec-13-19 01:55PM  Vertex and Republic of Ireland Expand Long-Term Cystic Fibrosis Medicines Reimbursement Agreement to Include Triple Combination Therapy for All Eligible Patients Ages 12 and Over Once Licensed Business Wire
Dec-12-19 02:37PM  Stocks Hit Records on China Trade Hope & Buy this Biotech Stock - Free Lunch Zacks
10:53AM  New Strong Buy Stocks for December 12th Zacks
Dec-11-19 02:42PM  Vertex's Kalydeco Gets EU Approval to Treat CF in Infants Zacks
12:45PM  Looking for a Growth Stock? 3 Reasons Why Vertex (VRTX) is a Solid Choice Zacks
09:41AM  Biotech Stock Roundup: ASH Data in Focus, Amgen Gets FDA Nod to Remicade Biosimilar Zacks
07:24AM  The Zacks Analyst Blog Highlights: Spark Energy, Vertex, ResMed, Prologis and Boston Beer Zacks
Dec-10-19 08:09AM  5 Defensive Stocks to Buy as Volatility Index Soars Zacks
06:57AM  Vertex Announces European Commission Approval for KALYDECO® (ivacaftor) in Infants With Cystic Fibrosis Ages 6 Months to Less Than 12 Months With Certain Mutations in the CFTR Gene Business Wire
Dec-09-19 09:55AM  Blueprint's (BPMC) Systemic Mastocytosis Study Data Impresses Zacks
09:52AM  Gilead (GILD) Announces Positive Long-Term Data on Yescarta Zacks
Dec-06-19 07:00AM  Three Stocks from the Zacks #1 Rank Uptrends Screen Zacks
Dec-05-19 03:53PM  Spero Posts Preliminary Data on SPR720 for Pulmonary Disease Zacks
03:49AM  Gene Therapy the Next Best Thing: Here's Why (Revised) Zacks
Dec-04-19 10:25AM  Biogen's Lupus Candidate Meets Endpoint in Phase II Study Zacks
09:42AM  Gene Therapy the Next Best Thing: Here's Why Zacks
Dec-03-19 10:45AM  Seattle Genetics, Astellas Tie Up With Merck for Cancer Study Zacks
08:59AM  Puma Biotech Expands Pierre Fabre License to Add Countries Zacks
Dec-02-19 11:00AM  Looking For Growth? Take A Look At These Biotechnology Stocks Investor's Business Daily
10:22AM  Acorda (ACOR) Down More Than 80% Year to Date: Here's Why Zacks
09:09AM  In the money Dec. 2: $49M reported raised American City Business Journals
Nov-29-19 12:15PM  Biotech Tops in November: Best ETFs & Stocks Zacks
Nov-28-19 07:02PM  Hedge Funds Are Warming Up To Vertex Pharmaceuticals Incorporated (VRTX) Insider Monkey
08:10AM  Incyte's NDA for Pemigatinib Gets FDA's Priority Review Tag Zacks
Nov-27-19 08:24AM  The Zacks Analyst Blog Highlights: Vertex, Biogen, BioMarin and Alexion Zacks
06:52AM  Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? Zacks
Nov-26-19 07:06PM  Why Biotech ETFs Surged in Monday's Trading Session Zacks
10:50AM  Vertex Pharma Shares Are Surging with Huge Demand Investopedia
06:07AM  4 Big Drug Stocks Ripe for Takeover After NVS-MDCO Deal Zacks
Nov-25-19 06:55PM  Genomics ETFs Surge on CRISPR's Gene Editing Progress Zacks
10:06AM  Biotech Stocks Awaken From Long Slumber Investopedia
Nov-22-19 09:43AM  Amgen (AMGN) Completes Otezla Buyout, Raises 2019 Guidance Zacks
Nov-21-19 10:24AM  Vertex (VRTX) Gets French Reimbursement for CF Drug Orkambi Zacks
08:00AM  Vertex Pharmaceuticals Shares March Higher, Can It Continue? Zacks
Nov-20-19 10:45AM  Crispr Therapeutics Rises After Company Announces Stock Sale Barrons.com
09:50AM  The Zacks Analyst Blog Highlights: Alexion Pharmaceuticals, Vertex Pharmaceuticals, Incyte and Regeneron Pharmaceuticals Zacks
09:31AM  Biotech Stock Roundup: MYOV & KRTX Surge, Pipeline Updates From VRTX, CELG & More Zacks
09:12AM  Vertex, CRISPR's Gene Editing Drug Shows Positive Early Data Zacks
07:25AM  The Daily Biotech Pulse: Endo's Cellulite Treatment Accepted For Review, Diffusion Pharma Reports Positive Glioblastoma Data Benzinga
05:00AM  French Authorities Approve National Reimbursement of ORKAMBI (lumacaftor/ivacaftor) for Eligible People Ages Two and Older With Cystic Fibrosis Business Wire
Nov-19-19 05:20PM  Biotech Stock Pops On Promising First In-Human CRISPR Gene-Editing Drug Investor's Business Daily
04:28PM  Biotech Stock Pops On Promising First In-Human CRISPR Gene-Editing Drug Investor's Business Daily
11:40AM  Crispr's Gene-Editing Therapy Found Effective In Treating Blood Disorders In Early-Stage Study Benzinga
11:25AM  Crispr Therapeutics Stock Spikes on Positive Gene-Editing Results Barrons.com
10:46AM  CRISPR Therapeutics stock jumps on early gene editing data American City Business Journals
10:14AM  4 Big Biotech Stocks Worth Considering Post Q3 Earnings Zacks
07:00AM  CRISPR Therapeutics and Vertex Announce Positive Safety and Efficacy Data From First Two Patients Treated With Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001® for Severe Hemoglobinopathies GlobeNewswire
Nov-15-19 10:20AM  Earnings Estimates Rising for Vertex (VRTX): Will It Gain? Zacks
05:38AM  Vertex Pharmaceuticals: The 'Endpoint' Is a Bullish Golden Cross TheStreet.com
Nov-14-19 05:14PM  US Market Mostly Lower Thursday GuruFocus.com
Nov-13-19 02:32PM  Ex-Novartis exec named as Flagship's matchmaker for Big Pharma partnerships American City Business Journals
07:55AM  UPDATE 1-Vertex deal with Wales expands cystic fibrosis treatment coverage to all of UK Reuters
07:08AM  Vertex reaches deal with Wales for cystic fibrosis treatment Reuters
06:29AM  Vertex Confirms Wales Offer Accepted for Access to All Licensed Cystic Fibrosis Medicines Business Wire
Nov-12-19 10:56AM  FDA intervenes for 3rd time in Solid Biosciences' Duchenne drug tests American City Business Journals
10:51AM  Vertex Confirms Northern Ireland Offer Accepted for Cystic Fibrosis Medicines Business Wire
Nov-11-19 09:05AM  Celgene & Acceleron Get FDA Nod for Rare Blood Disorder Drug Zacks
Nov-08-19 02:33PM  Sarepta (SRPT) Q3 Loss Widens Y/Y, Revenues Beat Estimates Zacks
02:20PM  FDA approves Acceleron's blood disorder drug ahead of schedule American City Business Journals
08:56AM  Arena Pharmaceuticals' (ARNA) Q3 Loss Widens, Revenues Beat Zacks
08:34AM  Moving Average Crossover Alert: Vertex Pharmaceuticals Zacks
Nov-07-19 04:01PM  Vertex to Present at the Credit Suisse Healthcare Conference on November 12 Business Wire
11:04AM  Esperion (ESPR) Reports Wider-Than-Expected Loss in Q3 Zacks
10:46AM  Puma (PBYI) Q3 Earnings Beat, Nerlynx Sales Weak, Stock Down Zacks
08:50AM  Geron (GERN) Q3 Earnings Beat Estimates, Stock Gains 4.1% Zacks
06:08AM  These 36 Mass. firms made Deloitte's Technology Fast 500 American City Business Journals
Nov-06-19 11:16AM  Don't Sell Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Before You Read This Simply Wall St.
10:56AM  Perrigo (PRGO) Beats on Q3 Earnings, Tightens '19 EPS View Zacks
Nov-05-19 10:00AM  Looking For Growth? Take A Look At These Biotechnology Stocks Investor's Business Daily
08:32AM  Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? Zacks
Nov-04-19 05:39PM  Edited Transcript of VRTX earnings conference call or presentation 30-Oct-19 9:00pm GMT Thomson Reuters StreetEvents
Nov-01-19 07:38AM  The Daily Biotech Pulse: Amgen Takes 20.5% Stake In BeiGene, Paratek's Mixed Clinical Readout, CareDx Slips On Guidance Benzinga
Oct-31-19 01:12PM  Celgene (CELG) Q3 Earnings Beat, Otezla, Revlimid Sales Rise Zacks
12:33PM  Vertex (VRTX) Q3 Earnings Beat, Revenues Lag Estimates Zacks
12:15PM  Phase 3 Results from Two Studies of TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) Triple Combination Treatment for Cystic Fibrosis Concurrently Published in The New England Journal of Medicine and The Lancet Business Wire
12:09PM  Vertex Pharmaceuticals Posts Strong 3rd-Quarter Revenue Growth GuruFocus.com
08:08AM  The Daily Biotech Pulse: Agile Receives Favorable Adcom Verdict, Merit Medical Tumbles On Earnings, 2 Biotechs To Debut Benzinga
07:21AM  Vertex Announces European Medicines Agency Marketing Authorization Application Validation for VX-445 (Elexacaftor), Tezacaftor and Ivacaftor Triple Combination Treatment in Cystic Fibrosis Business Wire
07:07AM  Will Vertex Pharmaceuticals Continue to Surge Higher? Zacks
Oct-30-19 05:15PM  Vertex Pharmaceuticals (VRTX) Beats Q3 Earnings Estimates Zacks
04:55PM  Will The No. 1 Biotech Stock Sacrifice Its Breakout On A Mixed Quarter? Investor's Business Daily
04:01PM  Vertex Reports Third-Quarter 2019 Financial Results Business Wire
12:51PM  Vertex Earnings Beat, Revenue Misses In Q3 Investing.com
10:53AM  Zacks.com featured highlights include: Columbia Sportswear, Boot Barn, Vertex Pharmaceuticals, Upland Software and Spotify Technology Zacks
Oct-29-19 01:00PM  12 Stocks With The Highest Returns On Assets Benzinga
12:17PM  VRTX Keeps Going Vertical Investor's Business Daily Video
09:28AM  Looking for an Earnings Beat? 5 Top Picks Zacks
Oct-28-19 02:58PM  BTIG: Crispr Could Be A Takeover Target For Vertex Benzinga
10:54AM  The Zacks Analyst Blog Highlights: Vertex Pharmaceuticals, PulteGroup, Skyworks Solutions, Lennar and Kansas City Southern Zacks
09:39AM  Google Breaks Out, Leading 5 Stocks With $1.8 Trillion Market Cap Near Buy Points Investor's Business Daily
Oct-25-19 12:06PM  Can CF Drugs Drive Growth for Vertex (VRTX) in Q3 Earnings? Zacks
09:21AM  Top Ranked Momentum Stocks to Buy for October 25th Zacks
09:20AM  5 Biotech Stocks to Buy for a Strong Growth Prognosis InvestorPlace
07:47AM  5 Top Volatility-Defying S&P 500 Stocks of Past Month Zacks
07:00AM  A Biotech Giant Not Named Biogen Also Had a Good Week Bloomberg
Oct-24-19 02:04PM  Drugs, data and the darknet: Cybersecurity a growing threat in the life sciences American City Business Journals
11:09AM  The Zacks Analyst Blog Highlights: Biogen, Vertex, Amgen, Alexion and Achillion Pharmaceuticals Zacks
10:50AM  5 Drug/Biotech Stocks Likely to Surpass on Earnings in Q3 Zacks
10:39AM  Baxter (BAX) Misses Q3 Revenue Estimates, Issues Guidance Zacks
09:54AM  AstraZeneca (AZN) Q3 Earnings Top, Upgrades '19 Sales View Zacks
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene. It is also developing VX-659 and VX-445 that are Phase III clinical trials; VX-121, a cystic fibrosis transmembrane conductance regulator corrector that is in Phase I/II clinical trial; VX-150, an inhibitor that is in Phase IIb clinical trial for acute pain; CTX001 that is in Phase I/II clinical trial for the treatment of beta-thalassemia and sickle cell diseases; and a novel drug candidate, which is in Phase I clinical trial for the treatment for alpha-1 antitrypsin deficiency. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna Therapeutics, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; Kymera Therapeutics; Ribometrix, Inc.; and Molecular Templates, Inc. The company was founded in 1989 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sachdev AmitEVP, Chief Patient OfficerDec 09Option Exercise109.145,000545,70038,416Dec 10 04:49 PM
Sachdev AmitEVP, Chief Patient OfficerDec 09Sale225.005,0001,125,00033,416Dec 10 04:49 PM
ALTSHULER DAVIDEVP, Global Research and CSONov 25Option Exercise187.533,910733,24235,463Nov 26 04:11 PM
Kewalramani ReshmaEVP and CMONov 25Option Exercise187.534,692879,89117,790Nov 26 04:12 PM
Sachdev AmitEVP, Chief Patient OfficerNov 25Option Exercise109.145,000545,70038,416Nov 26 04:13 PM
ALTSHULER DAVIDEVP, Global Research and CSONov 25Sale219.373,910857,73731,553Nov 26 04:11 PM
Kewalramani ReshmaEVP and CMONov 25Sale219.374,6921,029,28413,098Nov 26 04:12 PM
Sachdev AmitEVP, Chief Patient OfficerNov 25Sale220.005,0001,100,00033,416Nov 26 04:13 PM
Sachdev AmitEVP, Chief Patient OfficerNov 19Option Exercise109.145,000545,70038,416Nov 21 04:19 PM
LEIDEN JEFFREY MCEO & PresidentNov 19Option Exercise116.8096,53411,275,141202,880Nov 21 04:21 PM
Sachdev AmitEVP, Chief Patient OfficerNov 19Sale215.005,0001,075,00033,416Nov 21 04:19 PM
LEIDEN JEFFREY MCEO & PresidentNov 19Sale210.9196,53420,360,052106,346Nov 21 04:21 PM
LEIDEN JEFFREY MCEO & PresidentNov 18Option Exercise116.804,434517,893109,287Nov 19 04:12 PM
LEIDEN JEFFREY MCEO & PresidentNov 18Sale210.004,434931,140106,346Nov 19 04:12 PM
LEIDEN JEFFREY MCEO & PresidentNov 15Option Exercise116.805,000583,988109,663Nov 19 04:12 PM
ALTSHULER DAVIDEVP, Global Research and CSONov 15Sale205.956012,35731,553Nov 19 04:07 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerNov 15Sale205.95193,91333,240Nov 19 04:09 PM
Kewalramani ReshmaEVP and CMONov 15Sale205.956112,56313,098Nov 19 04:11 PM
LEIDEN JEFFREY MCEO & PresidentNov 15Sale210.005,0001,050,000106,346Nov 19 04:12 PM
Parini MichaelEVP, CL&AONov 15Sale205.958417,30035,003Nov 19 04:15 PM
Sachdev AmitEVP, Chief Patient OfficerNov 15Sale205.955711,73933,416Nov 19 04:16 PM
Tatsis OuraniaSVP, CRONov 15Sale205.9551,0307,252Nov 19 04:17 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerNov 13Option Exercise155.578,5601,331,67941,800Nov 15 04:03 PM
Parini MichaelEVP, CL&AONov 13Option Exercise155.574,892761,04839,895Nov 15 04:05 PM
Tatsis OuraniaSVP, CRONov 13Option Exercise155.572,853443,84110,105Nov 15 04:07 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerNov 13Sale205.578,5601,759,67933,240Nov 15 04:03 PM
Parini MichaelEVP, CL&AONov 13Sale205.504,8921,005,30635,003Nov 15 04:05 PM
Tatsis OuraniaSVP, CRONov 13Sale205.592,853586,5487,252Nov 15 04:07 PM
Kewalramani ReshmaEVP and CMONov 08Option Exercise155.5750979,18513,607Nov 13 04:08 PM
Kewalramani ReshmaEVP and CMONov 08Sale199.00509101,29113,098Nov 13 04:08 PM
ALTSHULER DAVIDEVP, Global Research and CSONov 06Option Exercise155.571,223190,26232,776Nov 07 04:36 PM
ALTSHULER DAVIDEVP, Global Research and CSONov 06Sale197.211,223241,18931,553Nov 07 04:36 PM
ALTSHULER DAVIDEVP, Global Research and CSONov 04Option Exercise88.494,126365,11735,679Nov 06 04:10 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerNov 04Option Exercise89.153,708330,57835,395Nov 06 04:11 PM
Parini MichaelEVP, CL&AONov 04Option Exercise86.522,330201,59237,333Nov 06 04:13 PM
Sachdev AmitEVP, Chief Patient OfficerNov 04Option Exercise88.904,097364,23537,513Nov 06 04:15 PM
ALTSHULER DAVIDEVP, Global Research and CSONov 04Sale200.454,126827,04931,553Nov 06 04:10 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerNov 04Sale201.623,708747,60733,240Nov 06 04:11 PM
Parini MichaelEVP, CL&AONov 04Sale200.502,330467,16835,003Nov 06 04:13 PM
Sachdev AmitEVP, Chief Patient OfficerNov 04Sale200.344,097820,79533,416Nov 06 04:15 PM
Bhatia Sangeeta N.DirectorNov 01Option Exercise152.741,291197,1876,540Nov 04 04:11 PM
Kearney Terrence CDirectorNov 01Option Exercise79.1747,4483,756,36725,811Nov 04 04:15 PM
LEIDEN JEFFREY MCEO & PresidentNov 01Option Exercise115.3796,82211,170,756176,577Nov 04 04:13 PM
Bhatia Sangeeta N.DirectorNov 01Sale200.001,291258,2005,249Nov 04 04:11 PM
Kearney Terrence CDirectorNov 01Sale200.0050,60710,121,4005,811Nov 04 04:15 PM
LEIDEN JEFFREY MCEO & PresidentNov 01Sale200.0296,82219,365,992106,287Nov 04 04:13 PM
LEIDEN JEFFREY MCEO & PresidentOct 31Option Exercise131.898,8791,171,051115,166Nov 04 04:13 PM
Kearney Terrence CDirectorOct 31Sale200.001,841368,2008,970Nov 04 04:15 PM
LEIDEN JEFFREY MCEO & PresidentOct 31Sale200.008,8791,775,800106,287Nov 04 04:13 PM
Kewalramani ReshmaEVP and CMOOct 30Option Exercise155.573,057475,57716,155Oct 31 04:36 PM
Kewalramani ReshmaEVP and CMOOct 30Sale199.003,057608,34313,098Oct 31 04:36 PM
Sachdev AmitEVP, Chief Patient OfficerOct 25Option Exercise91.054,311392,51737,727Oct 29 04:54 PM
Sachdev AmitEVP, Chief Patient OfficerOct 25Sale195.014,311840,68833,416Oct 29 04:54 PM
ALTSHULER DAVIDEVP, Global Research and CSOOct 22Option Exercise155.573,669570,78635,222Oct 24 07:13 PM
LEIDEN JEFFREY MCEO & PresidentOct 22Option Exercise116.61107,83112,574,276178,707Oct 24 07:23 PM
MCGLYNN MARGARET GDirectorOct 22Option Exercise72.1420,0001,442,80024,124Oct 24 07:26 PM
Sachdev AmitEVP, Chief Patient OfficerOct 22Option Exercise86.523,883335,95737,299Oct 24 07:28 PM
Sachdev AmitEVP, Chief Patient OfficerOct 22Sale190.273,883738,81833,416Oct 24 07:28 PM
MCGLYNN MARGARET GDirectorOct 22Sale190.0020,0003,800,0004,124Oct 24 07:26 PM
LEIDEN JEFFREY MCEO & PresidentOct 22Sale190.00107,83120,487,890106,287Oct 24 07:23 PM
Kewalramani ReshmaEVP and CMOOct 22Sale189.00638120,58213,098Oct 24 07:18 PM
ALTSHULER DAVIDEVP, Global Research and CSOOct 22Sale194.373,669713,14431,553Oct 24 07:13 PM
Parini MichaelEVP, CL&AOOct 17Option Exercise122.454,250520,41339,253Oct 21 04:29 PM
Parini MichaelEVP, CL&AOOct 17Sale177.804,250755,65035,003Oct 21 04:29 PM
Parini MichaelEVP, CL&AOOct 14Option Exercise90.292,125191,86637,128Oct 16 04:14 PM
Parini MichaelEVP, CL&AOOct 14Sale174.062,125369,88535,003Oct 16 04:14 PM
Bhatia Sangeeta N.DirectorOct 02Option Exercise126.517,088896,67613,628Oct 04 04:11 PM
Bhatia Sangeeta N.DirectorOct 02Sale166.808,3791,397,6405,249Oct 04 04:11 PM
Tatsis OuraniaSVP, CROOct 02Sale167.6944474,4547,252Oct 03 04:25 PM
Tatsis OuraniaSVP, CROOct 01Sale169.1118831,7937,696Oct 03 04:25 PM
ALTSHULER DAVIDEVP, Global Research and CSOAug 19Option Exercise103.2512,5011,290,68136,212Aug 20 04:30 PM
ALTSHULER DAVIDEVP, Global Research and CSOAug 19Sale186.3812,5012,329,97631,553Aug 20 04:30 PM
MCGLYNN MARGARET GDirectorAug 13Option Exercise81.5410,000815,40014,124Aug 15 04:11 PM
MCGLYNN MARGARET GDirectorAug 13Sale185.0010,0001,850,0004,124Aug 15 04:11 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerAug 08Option Exercise131.892,125280,26635,365Aug 12 04:14 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerAug 08Sale181.892,125386,51633,240Aug 12 04:14 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerAug 05Option Exercise86.521,553134,36633,793Aug 06 04:41 PM
Parini MichaelEVP, CL&AOAug 05Option Exercise86.522,330201,59237,333Aug 06 04:43 PM
Parini MichaelEVP, CL&AOAug 05Sale175.282,330408,39935,003Aug 06 04:43 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerAug 05Sale176.441,553274,01132,240Aug 06 04:41 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerAug 02Option Exercise91.052,155196,21334,395Aug 06 04:41 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerAug 02Sale177.782,155383,11632,240Aug 06 04:41 PM
Parini MichaelEVP, CL&AOJul 12Option Exercise90.292,125191,86637,128Jul 15 04:15 PM
Parini MichaelEVP, CL&AOJul 12Sale175.272,125372,45535,003Jul 15 04:15 PM
Parini MichaelEVP, CL&AOJul 05Option Exercise122.454,250520,41339,253Jul 09 04:49 PM
Parini MichaelEVP, CL&AOJul 05Sale179.114,250761,23935,003Jul 09 04:49 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJun 19Option Exercise131.892,125280,26635,365Jun 20 04:53 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJun 19Sale181.892,125386,51633,240Jun 20 04:53 PM
LEIDEN JEFFREY MCEO & PresidentJun 18Option Exercise77.3156,0304,331,679162,317Jun 20 04:43 PM
LEIDEN JEFFREY MCEO & PresidentJun 18Sale175.3956,0309,827,054106,287Jun 20 04:43 PM
Bhatia Sangeeta N.DirectorJun 03Sale167.08720120,2986,540Jun 04 04:08 PM
Parini MichaelEVP, CL&AOMay 30Sale173.00707122,31135,625May 06 04:08 PM
LEIDEN JEFFREY MCEO & PresidentMay 24Option Exercise77.31113,4328,769,428219,719May 28 05:45 PM
LEIDEN JEFFREY MCEO & PresidentMay 24Sale175.10113,43219,861,943106,287May 28 05:45 PM
Sachdev AmitEVP, CROMay 15Sale165.416110,09033,416May 17 04:37 PM
Silva Paul MSVP & ControllerMay 15Sale165.4116126,63117,759May 17 04:31 PM
Parini MichaelEVP, CL&AOMay 15Sale165.418313,72935,003May 17 04:29 PM
Kewalramani ReshmaEVP and CMOMay 15Sale165.4124139,86413,736May 17 04:21 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerMay 15Sale165.4113322,00033,240May 17 04:18 PM
ALTSHULER DAVIDEVP, Global Research and CSOMay 15Sale165.419115,05231,553May 17 04:16 PM
open in yahoo | open in reuters | open in google